What are the alternatives to Rybelsus (semaglutide) for the management of type 2 diabetes?

Alternatives to Rybelsus (Semaglutide) for Type 2 Diabetes Management

For patients requiring an alternative to Rybelsus (oral semaglutide), other GLP-1 receptor agonists like liraglutide, dulaglutide, or injectable semaglutide are the most appropriate substitutes, offering similar glycemic control and cardiovascular benefits. 1

GLP-1 Receptor Agonist Alternatives

Injectable GLP-1 Receptor Agonists

• Liraglutide (Victoza): Once-daily injection that has demonstrated significant cardiovascular benefits, including reduction in major adverse cardiovascular events (MACE) by 13% and cardiovascular death by 22% in the LEADER trial 1
• Injectable Semaglutide (Ozempic): Once-weekly injection with superior glycemic control compared to other GLP-1 RAs and demonstrated 26% reduction in cardiovascular events in the SUSTAIN-6 trial 1
• Dulaglutide (Trulicity): Once-weekly injection that showed 12% reduction in cardiovascular events in the REWIND trial 1
• Exenatide (Byetta/Bydureon): Available as twice-daily (Byetta) or once-weekly (Bydureon) formulations with neutral cardiovascular effects 1, 2

Key Considerations for GLP-1 RA Selection

• Injectable semaglutide has shown greater weight loss effects compared to other GLP-1 RAs 1, 3
• Liraglutide is specifically FDA-approved for reducing cardiovascular death risk 1
• Dulaglutide offers convenient once-weekly dosing with proven cardiovascular benefits 1
• Common side effects across all GLP-1 RAs include nausea, vomiting, and diarrhea, which can be minimized by slow dose titration 1, 4

SGLT2 Inhibitor Alternatives

SGLT2 inhibitors represent another excellent alternative class, particularly for patients with specific comorbidities:

• Empagliflozin: Recommended for patients with established cardiovascular disease to reduce cardiovascular death risk 1
• Dapagliflozin: Particularly beneficial for patients with heart failure (with reduced or preserved ejection fraction) 1
• Canagliflozin: Effective for patients with diabetic kidney disease 1

Benefits of SGLT2 Inhibitors

• Reduce risk of heart failure hospitalizations 1
• Slow progression of chronic kidney disease 1
• Promote modest weight loss 1
• Low risk of hypoglycemia 1

Other Medication Classes to Consider

• DPP-4 Inhibitors (sitagliptin, linagliptin): Weight-neutral with low hypoglycemia risk, but with neutral cardiovascular effects 1
• Pioglitazone: May be considered for patients at high risk for stroke, with caution in those with heart failure risk 1
• Metformin: Remains the first-line therapy for type 2 diabetes and can be combined with any of the above alternatives 1, 5

Clinical Decision Algorithm

1. For patients with established cardiovascular disease:

   • First choice: Injectable GLP-1 RA (liraglutide or injectable semaglutide) 1
   • Alternative: SGLT2 inhibitor (empagliflozin preferred) 1

2. For patients with heart failure:

   • First choice: SGLT2 inhibitor (dapagliflozin or empagliflozin) 1
   • Alternative: GLP-1 RA (avoid saxagliptin) 1

3. For patients with chronic kidney disease:

   • First choice: SGLT2 inhibitor (if eGFR >30 mL/min/1.73m²) 1
   • Alternative: GLP-1 RA (liraglutide, dulaglutide, semaglutide) 1

4. For patients primarily concerned with weight management:

   • First choice: Injectable semaglutide 1, 3
   • Alternative: Other GLP-1 RAs or SGLT2 inhibitors 1

5. For patients with gastrointestinal intolerance to GLP-1 RAs:

   • Consider SGLT2 inhibitors or DPP-4 inhibitors 1

Important Clinical Considerations

• When switching from oral semaglutide to another GLP-1 RA, expect similar efficacy with injectable semaglutide but potentially greater weight loss 6, 3
• Avoid combining GLP-1 RAs with DPP-4 inhibitors as they work through similar pathways 1
• Monitor for gastrointestinal side effects with all GLP-1 RAs, which typically improve over time 1, 4
• SGLT2 inhibitors require monitoring for genital mycotic infections, volume depletion, and rare cases of diabetic ketoacidosis 1
• Canagliflozin has been associated with increased risk of lower limb amputations in some studies 1